Isis Innovation (Oxford, UK), the University of Oxford’s technology transfer company, has licensed patents based on the work of Oxford Professor Richard Moxon’s research group and research by Canada’s National Research Council Institute for Biological Science to Novartis Vaccines and Diagnostics.
Isis Innovation (Oxford, UK), the University of Oxford’s technology transfer company, has licensed patents based on the work of Oxford Professor Richard Moxon’s research group and research by Canada’s National Research Council Institute for Biological Science to Novartis Vaccines and Diagnostics. The patents cover a novel vaccine candidate against the meningococcus bacterium-Neisseria meningitidis-currently at the preclinical stage.
Currently, no vaccine is available to combat Nesseiria meningitidis serogroup B strains of the disease. The new vaccine is designed to combat this B strain, as well as all other meningococcal strains.
Novartis Vaccines and Diagnostics has received a worldwide exclusive license to the Isis-owned patent on the vaccine which targets lipopolyaccharide (LPS), a macromolecule present in large amounts on the surface of meningococci during disease. Preclinical proof of concept studies have illustrated that the LPS molecules are recognized by the immune system and have potential as vaccine candidates.
Isis release
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.